BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile— —Patients report improved quality of life and daily functioning with ORLADEYO— RESEARCH TRIANGLE PARK, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.(Nasdaq:BCRX) today announced new data on the long-term efficacy and safety of ORLADEYO (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients across all age groups. "T ...